Targeting rapidly cycling receptors CD2 and CD7 increases nanoparticle delivery to primary CD4+ T cells

Read full text
Authors: Paula M. Cevaal, Ammar Ali, Marcel Doerflinger, Christina Cortez-Jugo, Abigail Tan, Haiyin Liu, Moore Z. Chen, L J Wang, Merle Dayton, Liana Mackiewicz, Stanislav Kan, Matthew Faria
+8 more Céline Gubser, René P. M. Lafleur, Robert De Rose, Angus P. R. Johnston, Frank S Caruso, Michael Roche, Jori Symons, Sharon R. Lewin
Cited by: 1
References: 62

Abstract

Abstract T cells are critically important to many diseases but are traditionally difficult to transfect. We hypothesise that the delivery of therapeutic cargo to T cells can be improved by targeting nanoparticles to surface receptors that undergo rapid receptor-mediated endocytosis. Using an internalisation assay that labelled intracellular and surface proteins with different fluorophores, we find that CD2 and CD7 exhibit significantly higher internalisation than other T cell receptors, such as CD3 or CD4. Targeting CD2 and CD7 improves nanoparticle internalisation by non-stimulated, primary CD4 + T cells and enhances the specificity of association to CD4 + T cells. Similarly, functionalising mRNA-lipid nanoparticles with antibodies targeting CD2 or CD7 enhances mRNA delivery to CD4 + T cells in vitro. Importantly, targeting CD2 or CD7 enables efficient lipid nanoparticle-mediated delivery of mRNA to T cells in blood and lymphoid tissue in vivo, demonstrating that targeting T cell receptor endocytosis can enhance nanoparticle-mediated drug delivery to T cells.

Fields of Study & Subjects

RNA Interference and Gene Delivery Immunotherapy and Immune Responses CAR-T cell therapy research

Publication details

Journal / source
Nature Communications
Publisher
Springer Science and Business Media LLC
Volume
17
Issue
1
Publication date
1 July 2026
Language
EN